This message was sent to ##Email##
|
|
|
|
|
| |
| HEALTH CARE NEWS AND UPDATES |
The JAMA Network
On May 23, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for patients with unresectable or metastatic, microsatellite instable-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors that have progressed on prior therapy and have no satisfactory treatment options. This approval is, to date, the first drug authorized for use based on a molecular biomarker rather than a traditional histopathologic diagnosis.
READ MORE
Cancer Network via Modern Medicine
The U.S. Food and Drug Administration (FDA) has approved nivolumab (Opdivo) for the adjuvant treatment of patients with melanoma and involvement of lymph nodes or metastatic disease who have undergone complete resection. Nivolumab is the first programmed death 1 (PD-1) inhibitor to show superiority compared with the standard of care, ipilimumab, in this patient population.
READ MORE
|
Promoted by
|
|
|
|
 |
Cancer Network via Modern Medicine
Dual HER2 blockade using lapatinib and trastuzumab along with aromatase inhibitor (AI) therapy was more effective than trastuzumab and an AI alone in a phase III trial of patients with HER2-positive, hormone receptor (HR)-positive metastatic breast cancer. Dual HER2 blockade has been shown to improve outcomes along with chemotherapy in the first-line setting of HER2-positive metastatic breast cancer.
READ MORE
The Medical News
Mount Sinai researchers have discovered that normal immune cells called macrophages, which reside in healthy breast tissue surrounding milk ducts, play a major role in helping early breast cancer cells leave the breast for other parts of the body, potentially creating metastasis before a tumor has even developed, according to a study published in Nature Communications.
READ MORE
| |
PRODUCT SHOWCASE | Advertisement
|
 |
|
Enjoy our journals? There’s an app for those! Journals such as those from the American Cancer Society ™, Journal of Surgical Oncology, Cancer Science and more are now available for your iPad and iPhone. Sample issues and abstracts, as well as open articles, can be accessed for free. A subscription to the journal is required to read the full text. Click here to learn more!
|
|
Dana-Farber Cancer Institute via Medical Xpress
Reporting in the Proceedings of the National Academy of Sciences, investigators demonstrated in cancer cell lines and animal models that the research compounds — similar to common anti-diabetic agents known as thiazolidinediones (TZDs) — sensitized lung tumor cells to carboplatin chemotherapy. Tumors in rodents treated with the combination of carboplatin and one of the experimental compounds, SR1664, weighed less than those in animals treated with carboplatin alone.
READ MORE
American College of Physicians
The U.S. Preventive Services Task Force recommends annual lung cancer screening with low-dose computed tomography (CT) for persons aged 55 to 80 years who currently smoke or quit within the past 15 years and have at least a 30-pack-year history of cigarette smoking. These criteria may miss smokers at high risk for lung cancer who would have been selected for CT screening by individual risk calculators that more specifically account for demographic, clinical and smoking characteristics.
READ MORE
NCoBC
A breast surgeon’s goal is to eliminate cancer while achieving a cosmetic result that shows little evidence a surgical procedure had occurred. Use of oncoplastic surgery has dramatically increased nationwide over the last several years. The National Consortium of Breast Centers (NCoBC) recognizes the pivotal role of surgery in the overall management of the breast cancer patient and will be introducing an Oncoplastic Surgery Course at the NCoBC Annual Interdisciplinary Meeting in Las Vegas, Nev., March 10-11, 2018. This unique course will utilize the latest life-like models of a woman’s breasts with the ability to sew, cut and reconstruct tissue in real time. Nationally known surgeons will lecture, demonstrate and be present during the two-day, hands-on lab. Each participant will be able to both observe and perform multiple oncoplastic procedures on these models. For more information, visit the NCoBC 2018 Conference website. Early registration is suggested.
| ACS CANCER PROGRAMS AND UPDATES |
ACS-NCDB
The Commission on Cancer (CoC) is committed to assisting accredited cancer programs with maintaining the highest level of data quality possible. We appreciate your facility's participation and contribution to the National Cancer Database (NCDB). Data submissions are essential for assessing and improving the quality of cancer patient care. The information generated from the NCDB enables cancer programs to compare treatment and outcomes with regional, state and national patterns.
READ MORE
ACS-AJCC
The American Joint Committee on Cancer (AJCC) will be conducting a number of webinars on the AJCC Cancer Staging Manual, Eighth Edition in 2018. The webinars are scheduled as follows: Feb. 15, 2018 - Minor Rule Changes; March 20, 2018 - Major Rule Changes; April 17, 2018 - CAnswer Forum and Staging Questions; July 25, 2018 - Head and Neck Staging; and Sept. 6, 2018 - Breast Staging. All webinars will be held from 1:00 to 2:00 pm CT. Make sure to mark your calendars. Visit the AJCC website for updates, additional information and registration links.
READ MORE
 |
|
Novodiax is soon bringing to market 10-minute fast, sensitive and simple Immunoassay (IHC) kits for in vitro diagnostic use to address unmet needs in the intraoperative surgical oncology sector. Learn More
|
|
CoC and NAPBC
Beginning January 1, 2018, both the Commission on Cancer (CoC) and the National Accreditation Program for Breast Centers (NAPBC) are introducing new annual accreditation fees.
READ MORE
ACS CRP
The American College of Surgeons (ACS) Clinical Research Program (CRP) invites you to attend a live webinar on Wednesday, January 10 from 10:00 to 11:00 am (CST) that will provide an update on Ongoing Breast Cancer Cooperative Group Clinical Trials. The webinar will focus on A11106 (Alternate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant Treatment [ALTERNATE] in postmenopausal women) and AFT-25 (Comparison of Operative to Monitoring and choice of Endocrine Therapy [COMET] Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial). Register today.
READ MORE
ACS Quality Programs
The 2018 ACS Quality and Safety Conference: Partners in Quality will be held in Orlando, July 21-24. This education program brings health care professionals together to discuss and apply current knowledge pertaining to national and local quality initiatives in the field of surgery. Attendees will learn techniques to manage, analyze and interpret data to make a positive impact at their facilities.
READ MORE
 |
|
Donate now to help Doctors Without Borders bring emergency medical care where it is needed most. Doctors Without Borders USA relies on unrestricted donations from private donors so when an emergency strikes we assess the needs and can act fast. Donate today.
|
|
| IMPORTANT DATES AND DEADLINES |
| Date |
Event |
Location |
| Jan. 10, 2018 |
Ongoing Breast Cancer Cooperative Group Clinical Trials
|
Webinar
|
| Jan. 26, 2018 |
ACS Quality and Safety Conference Abstract Submission Closes
|
|
| Feb. 15, 2018 |
AJCC Staging Manual Eighth Edition Minor Rule Changes
|
Webinar (1-2 pm CT)
|
| March 20, 2018 |
AJCC Staging Manual Eighth Edition Major Rule Changes
|
Webinar (1-2 pm CT)
|
| Apr. 17, 2018 |
AJCC Staging Manual Eighth Edition CAnswer Forum and Staging Questions
|
Webinar (1-2 pm CT)
|
| July 21-24, 2018 |
ACS Quality and Safety Conference
|
Orlando
|
| July 25, 2018 |
AJCC Staging Manual Eighth Edition Head and Neck Staging
|
Webinar (1-2 pm CT)
|
| Sept. 6, 2018 |
AJCC Staging Manual Eighth Edition Breast Staging
|
Webinar (1-2 pm CT)
|
| Oct. 21-25, 2018 |
ACS Clinical Congress
|
Boston, MA
|
|
Missed last week's issue? See which articles your colleagues read most.
|
Don't be left behind. Click here to see what else you missed.
|
|
|
|
The Brief
Connect with AJCC
Connect with CoC
Connect with NAPBC
Recent Issues | Subscribe | Unsubscribe | Advertise | Web Version
Colby Horton, Vice President of Publishing, 469-420-2601 | Download media kit
Ashley Harrington, Senior Content Editor, 469-420-2642 | Contribute news
Disclaimer: The Brief is a digest of news selected for the Commission on Cancer (CoC) and the National Accreditation Program for Breast Centers (NAPBC), both quality programs of the American College of Surgeons, from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The CoC and NAPBC do not endorse any of the advertised products and services. Opinions expressed in the articles are those of the author and not of the American College of Surgeons, the CoC and the NAPBC.
American College of Surgeons
633 N Saint Clair Street | Chicago, IL, 60611-3211 | 800-621-4111 | Contact Us
Learn how to add us to your safe sender list so our emails get to your inbox. |
|
| |
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
